[Real-world experience with aflibercept 8 mg for treatment of neovascular age-related macular degeneration after 12 months]
{{output}}
Background: The phase 3 clinical trial PULSAR demonstrated extended treatment intervals with aflibercept 8 mg in treatment-naïve eyes with neovascular age-related macular degeneration (nAMD) in a large proportion of the cohort, ... ...
